RHJA
OBIO icon

Rice Hall James & Associates’s Orchestra BioMed OBIO Stock Holding History

Rice Hall James & Associates’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.8K Buy
+19,001
New +$80.9K ﹤0.01% 243

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Rice Hall James & Associates's OBIO Position: Q1 2026 in Review

Rice Hall James & Associates opened a new position in Orchestra BioMed (OBIO) in Q1 2026: 19,001 shares worth $80.8K. The stake represents ﹤0.01% of the portfolio and ranks #243 among its holdings.

65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Rice Hall James & Associates held 19,001 shares of Orchestra BioMed worth $80.8K as of Q1 2026.
  • Orchestra BioMed was a new Rice Hall James & Associates position in Q1 2026.
  • Orchestra BioMed made up ﹤0.01% of Rice Hall James & Associates's portfolio in Q1 2026, its #243 holding.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.